These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
69 related articles for article (PubMed ID: 7883388)
1. Immune response in patients with intra-abdominal infections treated with carbapenems. Brismar B; Eklund AE; Nord CE Int J Clin Pharmacol Res; 1994; 14(3):111-4. PubMed ID: 7883388 [TBL] [Abstract][Full Text] [Related]
2. Meropenem versus imipenem/cilastatin in the treatment of sepsis in Chinese patients. Kuo BI; Fung CP; Liu CY Zhonghua Yi Xue Za Zhi (Taipei); 2000 May; 63(5):361-7. PubMed ID: 10862445 [TBL] [Abstract][Full Text] [Related]
3. Multicenter randomized trial comparing meropenem (1.5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia. Bartoloni A; Strohmeyer M; Corti G; Buonomini MI; Franchino L; Romanelli G; Moretti AM; De Vizzi GB; Petraglia A; Mancini P; Atzeni R; Fogliani V; Giura R; Paradisi F Drugs Exp Clin Res; 1999; 25(6):243-52. PubMed ID: 10713862 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Lucasti C; Jasovich A; Umeh O; Jiang J; Kaniga K; Friedland I Clin Ther; 2008 May; 30(5):868-83. PubMed ID: 18555934 [TBL] [Abstract][Full Text] [Related]
5. A randomized, controlled clinical trial on meropenem versus imipenem/cilastatin for the treatment of bacterial infections. Hou F; Li J; Wu G; Zheng B; Chen Y; Gu J; Wang H; Huo L; Xue X; Jia C; Yin Y; Tian X; Ren S Chin Med J (Engl); 2002 Dec; 115(12):1849-54. PubMed ID: 12622937 [TBL] [Abstract][Full Text] [Related]
6. Carbapenems: monotherapy in intra-abdominal sepsis. Wilson SE Scand J Infect Dis Suppl; 1995; 96():28-33. PubMed ID: 7652500 [TBL] [Abstract][Full Text] [Related]
7. Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intra-abdominal infections. Niinikoski J; Havia T; Alhava E; Pääkkönen M; Miettinen P; Kivilaakso E; Haapiainen R; Matikainen M; Laitinen S Surg Gynecol Obstet; 1993 Mar; 176(3):255-61. PubMed ID: 8382381 [TBL] [Abstract][Full Text] [Related]
8. Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. Meropenem Study Group. Geroulanos SJ J Antimicrob Chemother; 1995 Jul; 36 Suppl A():191-205. PubMed ID: 8543495 [TBL] [Abstract][Full Text] [Related]
9. Effect of moxifloxacin versus imipenem/cilastatin treatment on the mortality of mice infected intravenously with different strains of Bacteroides fragilis and Escherichia coli. Schaumann R; Blatz R; Beer J; Ackermann G; Rodloff AC J Antimicrob Chemother; 2004 Feb; 53(2):318-24. PubMed ID: 14729746 [TBL] [Abstract][Full Text] [Related]
10. Treatment of acute bacterial exacerbations of chronic obstructive pulmonary disease in hospitalised patients--a comparison of meropenem and imipenem/cilastatin. COPD Study Group. Hamacher J; Vogel F; Lichey J; Kohl FV; Diwok K; Wendel H; Lode H J Antimicrob Chemother; 1995 Jul; 36 Suppl A():121-33. PubMed ID: 8543488 [TBL] [Abstract][Full Text] [Related]
11. Immune response in patients with intraabdominal infections treated with imipenem. Swedish Study Group. Infection; 1989; 17(6):369-73. PubMed ID: 2693357 [TBL] [Abstract][Full Text] [Related]
12. Is it safe to use carbapenems in patients with a history of allergy to penicillin? Sodhi M; Axtell SS; Callahan J; Shekar R J Antimicrob Chemother; 2004 Dec; 54(6):1155-7. PubMed ID: 15486083 [TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of imipenem/cilastatin in the therapy of severe infections in high-risk patients. Cristiano P Drugs Exp Clin Res; 1989; 15(1):17-20. PubMed ID: 2743870 [TBL] [Abstract][Full Text] [Related]
14. Changing role of carbapenems in the treatment of lower respiratory tract infections. Lode H; Hamacher J; Eller J; Schaberg T Scand J Infect Dis Suppl; 1995; 96():17-23. PubMed ID: 7652498 [TBL] [Abstract][Full Text] [Related]
15. Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections. Garau J; Blanquer J; Cobo L; Corcia S; Daguerre M; de Latorre FJ; León C; Del Nogal F; Net A; Rello J Eur J Clin Microbiol Infect Dis; 1997 Nov; 16(11):789-96. PubMed ID: 9447899 [TBL] [Abstract][Full Text] [Related]
16. Meropenem versus imipenem/cilastatin in the treatment of intraabdominal infections requiring surgery. Kanellakopoulou K; Giamarellou H; Papadothomakos P; Tsipras H; Chloroyiannis J; Theakou R; Sfikakis P Eur J Clin Microbiol Infect Dis; 1993 Jun; 12(6):449-53. PubMed ID: 8359165 [TBL] [Abstract][Full Text] [Related]
17. A post hoc subgroup analysis of meropenem versus imipenem/cilastatin in a multicenter, double-blind, randomized study of complicated skin and skin-structure infections in patients with diabetes mellitus. Embil JM; Soto NE; Melnick DA Clin Ther; 2006 Aug; 28(8):1164-1174. PubMed ID: 16982293 [TBL] [Abstract][Full Text] [Related]
18. Meropenem monotherapy is as effective as and safer than imipenem to treat brain abscesses. Martin-Canal G; Saavedra A; Asensi JM; Suarez-Zarracina T; Rodriguez-Guardado A; Bustillo E; Fierer J; Carton JA; Collazos J; Asensi V Int J Antimicrob Agents; 2010 Mar; 35(3):301-4. PubMed ID: 20045289 [TBL] [Abstract][Full Text] [Related]
19. [Meropenem (Merrem) vs imipenem/cilastatin in hospital treatment of intra-abdominal infections. A multicenter study]. Tonelli F Minerva Chir; 1997 Mar; 52(3):317-26. PubMed ID: 9148225 [TBL] [Abstract][Full Text] [Related]
20. Monobactams and carbapenems for treatment of intraabdominal infections. Brismar B; Nord CE Infection; 1999; 27(2):136-47. PubMed ID: 10219648 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]